VIT.AU Vitura Health Ltd
- Market cap
- AUD 13.3M
- P/E
- -
- P/B
- 0.30x
- ROE
- -10.1%
- Dividend yield
- 9.76%
- Fundamental score
- 2.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is VIT.AU undervalued?
Graham numberThe Graham number of Vitura Health Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vitura Health Ltd fundamental analysis
9 of 21 checks passedROE 0/2
Low return on equity (-10.1%), below 10%.
ROA 1/1
Return on assets (-5.7%) is above the industry median (-8.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-221.6%) is below the industry median (42.8%).
Revenue Growth 1/2
Revenue grew 3.8% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (37.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 24.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.3x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (9.8%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vitura Health Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vitura Health Ltd
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which …
Full company profileVitura Health Ltd financial statements
Vitura Health Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 18.0K | 448K | - | 124K | 21.7M | 67.0M | 117M | 124M | 124M | 131M |
| Gross Profit | 18.0K | 438K | -27.4K | 117K | 3.19M | 25.4M | 26.0M | 34.2M | 33.8M | 3.92M |
| Operating Income | -22.3K | -256K | -2.89M | -3.83M | 1.70M | 9.92M | 19.9M | 4.87M | 5.24M | -2.01M |
| EBITDA | 62.7K | 201K | -2.86M | -3.74M | 2.12M | 10.9M | 21.1M | 7.08M | 7.52M | 1.20M |
| Net Income | -22.3K | 150K | -2.91M | -3.94M | -4.05M | 6.05M | 13.8M | 3.51M | 3.32M | -4.39M |
| EPS | 0.00 | 0.00 | -0.02 | -0.04 | -0.01 | 0.01 | 0.02 | 0.01 | 0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 1.22K | 308K | 18.0M | 16.2M | 12.7M | 42.9M | 46.9M | 71.3M | 75.5M | 76.7M |
| Total Liabilities | 23.4K | 241K | 3.75M | 2.73M | 3.47M | 16.8M | 12.0M | 32.8M | 27.9M | 33.8M |
| Shareholders' Equity | -22.2K | 67.5K | 14.2M | 13.4M | 9.30M | 26.1M | 35.0M | 38.8M | 48.2M | 43.5M |
| Cash & Short-term Investments | 348.00 | 58.7K | 17.6M | 14.7M | 9.47M | 16.1M | 18.8M | 11.3M | 7.58M | 5.35M |
| Total Debt | 20.7K | 116K | 2.20M | 2.21M | 2.65M | 5.06M | 1.71M | 11.0M | 12.0M | 16.4M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -20.5K | 253K | -1.66M | -4.89M | 1.07M | 13.5M | 9.71M | 7.00M | 2.67M | -91.0K |
| Capital Expenditure | 0.00 | 104K | 7.18K | 269K | 60.2K | 377K | 928K | 786K | 83.5K | 126K |
| Free Cash Flow | -20.5K | 149K | -1.66M | -5.16M | 1.01M | 13.1M | 8.78M | 6.21M | 2.58M | -217K |
| Ratios | ||||||||||
| ROE | - | 222.9% | -20.5% | -29.3% | -43.6% | 23.2% | 39.5% | 9.1% | 6.9% | -10.1% |
| ROA | -1,828.2% | 48.7% | -16.2% | -24.3% | -31.9% | 14.1% | 29.4% | 4.9% | 4.4% | -5.7% |
| Net Profit Margin | -124.1% | 33.6% | - | -3,179.0% | -18.6% | 9.0% | 11.8% | 2.8% | 2.7% | -3.3% |
| Debt to Equity | - | 1.72x | 0.15x | 0.16x | 0.28x | 0.19x | 0.05x | 0.28x | 0.25x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vitura Health Ltd dividends
- Dividend yield
- 9.76%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 5, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 1.29M | 0.00 | - |
| 2025 | - | - | - |
| 2024 | AUD 5.44M | 0.01 | 154.8% |
| 2023 | AUD 5.46M | 0.01 | 39.6% |
| 2022 | AUD 1.50M | 0.00 | 24.9% |
| 2021 | AUD 335K | 0.00 | - |
| 2020 | AUD 19.9M | 0.22 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vitura Health Ltd
- Insiders 72.01%
- Institutions 1.28%
- Public & others 26.71%
- Shares outstanding 663M
- Free float 246M
Vitura Health Ltd company profile
- Company name
- Vitura Health Ltd
- Ticker
- VIT.AU
- ISIN
- AU0000266801
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- Suite 21, Level 3, South Yarra, VIC, Australia, 3141
- Phone
- 59 6 2907 1594
- Website
- vitura.com.au
About Vitura Health Ltd
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a therapy clinic that offers telehealth consultations. It also offers psychedelics under the Cortexa brand; Adaya, which provides hybrid formulations and Australian-cultivated products; Candor Medical, that provides care to patients; and inscape, which offers crafted formulations for individual needs. In addition, the company engages in the supply of MDMA and synthetic psilocybin for therapeutic purposes. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. Vitura Health Limited was incorporated in 2018 and is based in South Yarra, Australia.
Vitura Health Ltd management
5- Mr. Justin D. JamesChief Executive Officer
- Mr. James FrayneChief Financial Officer
- Ms. Trudy AdamsExecutive General Manager of Strategy, Technology & Risk
- Ms. Deanna JohnsExecutive GM of People & Culture
- Mr. Michael Sapountzis AGIA, B.Com., L.L.B., M.A.I.C.D.Company Secretary